EZH2 and diffuse large B-cell lymphoma: For instance, point mutations leading to EZH2 Y641 substitutions, which are gain of function alterations of EZH2, were found in both DLBCL and FL patients, potentially giving rise to treatment with EZH2 inhibitors such as Tazemetostat [5,34].